We saw no significant differences in the numbers of tumor-infiltrating CD4+ and CD8+ T cells between the treatment groups, although, interestingly, the number of CD8+ T cells in the PeptiBAC-AH1-treated tumors was slightly but non-significantly decreased compared with tumors from other treatment groups. The gene discussed is CD4; the disease is neoplasm.